Full FDA Approval for Camptosar

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka

FDA OKs Larotrectinib in Adult and Pediatric NTRK+ Tumor Populations

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.

Russ Conroy

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Ariana Pelosci

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Roman Fabbricatore

Bevacizumab Biosimilar Approved for Intravenous Use in Solid Tumors

Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

Related Content

Tim Cortese

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka

FDA OKs Larotrectinib in Adult and Pediatric NTRK+ Tumor Populations

Russ Conroy

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Ariana Pelosci

Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

Roman Fabbricatore